SONN sonnetbio.com: Enterprise Value to EBITDA Ratio

Graphic logo of Sonnet BioTherapeutics Holdings (SONN)

The EV/EBITDA price visualization for Sonnet BioTherapeutics (SONN), which develops tumor-fighting immune stimulants, currently stands at 0.00. The company's laboratory resources are fully utilized for research, and external facilities are ready for drug production. However, global conflicts are hindering international cooperation and the protection of intellectual property. Meanwhile, automation is assisting in drug design, although final oversight of treatment remains with medical professionals.

Sonnet BioTherapeutics Holdings, Inc. - SONN Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 12/13/2025)

Summary analytical data breakdowns for sonnetbio.com (SONN)

- stock price and consensus target price:
Stock Quotes Sonnet BioTherapeutics Holdings|SONN - Average Forecast Price
- company stock capitalization data:
Market Valuation Sonnet BioTherapeutics Holdings Inc.|SONN - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Sonnet BioTherapeutics|SONN - Book Valuation of Business|Market Value to Book Value Ratio sonnetbio.com|SONN - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Sonnet BioTherapeutics|SONN - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Sonnet BioTherapeutics Holdings|SONN - Company Aggregate Debts|Debt to Book Capitalization Ratio Sonnet BioTherapeutics Holdings Inc.|SONN - Company Long-Term Indebtedness|Company Short-Term Debt Sonnet BioTherapeutics|Quick Liquidity Indicator sonnetbio.com
- financial results and valuation multiples details:
SONN - Annual Net Income|Future Profit Sonnet BioTherapeutics|SONN - Market Price to Net Income Ratio|Forward P/E Multiple Sonnet BioTherapeutics Holdings|SONN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Sonnet BioTherapeutics Holdings Inc.|SONN - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Sonnet BioTherapeutics|SONN - Earnings per share for the trailing year|Quarterly EPS earnings growth sonnetbio.com|SONN - Earnings growth in current year|Net earnings per share growth forecast for next year Sonnet BioTherapeutics
- sales volume and revenue indicators:
SONN - Company Annual Revenue|Company Future Sales Volume Sonnet BioTherapeutics Holdings|SONN - Price to Sales|Price-to-Projected Revenue Ratio Sonnet BioTherapeutics Holdings Inc.
Fundamental company analysis:SONN (Sonnet BioTherapeutics Holdings Inc.)
Original product of Sonnet BioTherapeutics Holdings, Inc.

For a conservative investor, the dynamic EV/EBITDA metric of Sonnet BioTherapeutics (SONN) serves as a tool to compare the total enterprise value with its operating profit before interest and taxes, revealing the degree of fundamental undervaluation or debt load. In the case of Sonnet BioTherapeutics (SONN), the low values on the chart confirm the efficiency of the scalable FHAB platform, which enables the generation of new patents without excessive capital expenditures on research.

Competitor analysis for Sonnet BioTherapeutics

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA iobiotech.com (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple ALXO (ALX Oncology)|Business Value to Operating Income Before Depreciation CUE|PDS Biotechnology Corp - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio neximmune.com NEXI|turnstonebio.com (TSBX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Vaccinex Inc. (VCNX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx